Oxford Biomedica (OXB) Competitors GBX 426.50 +2.00 (+0.47%) (As of 12/20/2024 12:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades OXB vs. ONT, GNS, ERGO, SLN, PRTC, HZD, VRP, ARIX, BVXP, and FARNShould you be buying Oxford Biomedica stock or one of its competitors? The main competitors of Oxford Biomedica include Oxford Nanopore Technologies (ONT), Genus (GNS), Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Bioventix (BVXP), and Faron Pharmaceuticals Oy (FARN). These companies are all part of the "biotechnology" industry. Oxford Biomedica vs. Oxford Nanopore Technologies Genus Ergomed Silence Therapeutics PureTech Health Horizon Discovery Group plc (HZD.L) Verona Pharma plc (VRP.L) Arix Bioscience Bioventix Faron Pharmaceuticals Oy Oxford Biomedica (LON:OXB) and Oxford Nanopore Technologies (LON:ONT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations. Is OXB or ONT more profitable? Oxford Nanopore Technologies has a net margin of -94.82% compared to Oxford Biomedica's net margin of -145.98%. Oxford Nanopore Technologies' return on equity of -26.08% beat Oxford Biomedica's return on equity.Company Net Margins Return on Equity Return on Assets Oxford Biomedica-145.98% -124.66% -12.67% Oxford Nanopore Technologies -94.82%-26.08%-14.42% Do insiders & institutionals believe in OXB or ONT? 64.1% of Oxford Biomedica shares are held by institutional investors. Comparatively, 38.4% of Oxford Nanopore Technologies shares are held by institutional investors. 21.2% of Oxford Biomedica shares are held by company insiders. Comparatively, 32.6% of Oxford Nanopore Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts prefer OXB or ONT? Oxford Biomedica currently has a consensus target price of GBX 433.33, suggesting a potential upside of 1.60%. Oxford Nanopore Technologies has a consensus target price of GBX 235.50, suggesting a potential upside of 64.57%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Oxford Nanopore Technologies 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor OXB or ONT? In the previous week, Oxford Biomedica's average media sentiment score of 0.00 equaled Oxford Nanopore Technologies'average media sentiment score. Company Overall Sentiment Oxford Biomedica Neutral Oxford Nanopore Technologies Neutral Does the MarketBeat Community believe in OXB or ONT? Oxford Biomedica received 326 more outperform votes than Oxford Nanopore Technologies when rated by MarketBeat users. However, 100.00% of users gave Oxford Nanopore Technologies an outperform vote while only 66.73% of users gave Oxford Biomedica an outperform vote. CompanyUnderperformOutperformOxford BiomedicaOutperform Votes35966.73% Underperform Votes17933.27% Oxford Nanopore TechnologiesOutperform Votes33100.00% Underperform VotesNo Votes Which has preferable earnings & valuation, OXB or ONT? Oxford Biomedica has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Oxford Biomedica, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOxford Biomedica£97.28M4.62-£142.02M-£1.44-296.18Oxford Nanopore Technologies£167.75M8.03-£159.06M-£0.20-715.50 Which has more volatility and risk, OXB or ONT? Oxford Biomedica has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Oxford Nanopore Technologies has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. SummaryOxford Nanopore Technologies beats Oxford Biomedica on 10 of the 16 factors compared between the two stocks. Ad Porter & CompanyAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.I urge you to watch it now. Get Oxford Biomedica News Delivered to You Automatically Sign up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OXB vs. The Competition Export to ExcelMetricOxford BiomedicaBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£449.36M£165.68M£5.14B£1.90BDividend Yield4.57%3.64%5.09%5.55%P/E Ratio-296.18115.5190.051,821.81Price / Sales4.6218,531.021,117.09386,342.76Price / Cash3.0112.8743.1028.54Price / Book6.778.594.782.78Net Income-£142.02M-£20.67M£120.31M£157.16M7 Day Performance0.71%-1.05%-1.92%-2.00%1 Month Performance1.55%174.77%13.65%21.23%1 Year Performance116.50%134.18%28.34%29.20% Oxford Biomedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OXBOxford BiomedicaN/AGBX 426.50+0.5%GBX 433.33+1.6%+116.5%£449.36M£97.28M-296.18891Gap DownHigh Trading VolumeONTOxford Nanopore Technologies1.55 of 5 starsGBX 157.13+2.0%GBX 235.50+49.9%-30.7%£1.48B£167.75M-774.001,281Positive NewsGNSGenus1.4612 of 5 starsGBX 1,630-0.2%GBX 2,150+31.9%-30.6%£1.07B£668.80M13,616.67480ERGOErgomedN/AN/AN/AN/A£701.00M£152.09M4,641.386SLNSilence TherapeuticsN/AGBX 535-0.9%N/AN/A£480.35M£11.35M-11.01100News CoveragePositive NewsHigh Trading VolumePRTCPureTech Health2.247 of 5 starsGBX 170+4.4%GBX 455+167.6%+2.5%£407.01M£3.33M-745.89300News CoverageHigh Trading VolumeHZDHorizon Discovery Group plc (HZD.L)N/AGBX 184.50flatN/AN/A£302.98M£54.63M-33.55416VRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822News CoverageGap UpARIXArix BioscienceN/AN/AN/AN/A£183.73M£14.16M1,290.919BVXPBioventixN/AGBX 3,480.21+0.7%N/A-23.7%£181.67M£13.60M2,147.2412FARNFaron Pharmaceuticals OyN/AGBX 167.70+1.6%N/A-45.8%£175.45M£-725,000.00-531.2534 Related Companies and Tools Related Companies Oxford Nanopore Technologies Alternatives Genus Alternatives Ergomed Alternatives Silence Therapeutics Alternatives PureTech Health Alternatives Horizon Discovery Group plc (HZD.L) Alternatives Verona Pharma plc (VRP.L) Alternatives Arix Bioscience Alternatives Bioventix Alternatives Faron Pharmaceuticals Oy Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:OXB) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Biomedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
